User profiles for "author:C L Masters"

Colin Louis Masters

The University of Melbourne
Verified email at florey.edu.au
Cited by 152451

[HTML][HTML] The amyloid-β pathway in Alzheimer's disease

H Hampel, J Hardy, K Blennow, C Chen, G Perry… - Molecular …, 2021 - nature.com
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Alzheimer's disease

CL Masters, R Bateman, K Blennow… - Nature reviews disease …, 2015 - nature.com
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20
years) and an average clinical duration of 8–10 years. The disease has an estimated …

Neurodegenerative diseases and oxidative stress

KJ Barnham, CL Masters, AI Bush - Nature reviews Drug discovery, 2004 - nature.com
Oxidative stress has been implicated in the progression of Alzheimer's disease, Parkinson's
disease and amyotrophic lateral sclerosis. Oxygen is vital for life but is also potentially …

[HTML][HTML] Clinical and biomarker changes in dominantly inherited Alzheimer's disease

RJ Bateman, C Xiong, TLS Benzinger… - … England Journal of …, 2012 - Mass Medical Soc
Background The order and magnitude of pathologic processes in Alzheimer's disease are
not well understood, partly because the disease develops over many years. Autosomal …

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

CL Masters, G Simms, NA Weinman… - Proceedings of the …, 1985 - National Acad Sciences
We have purified and characterized the cerebral amyloid protein that forms the plaque core
in Alzheimer disease and in aged individuals with Down syndrome. The protein consists of …

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

VL Villemagne, S Burnham, P Bourgeat… - The Lancet …, 2013 - thelancet.com
Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …

[HTML][HTML] Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice

RA Cherny, CS Atwood, ME Xilinas, DN Gray… - Neuron, 2001 - cell.com
Inhibition of neocortical β-amyloid (Aβ) accumulation may be essential in an effective
therapeutic intervention for Alzheimer's disease (AD). Cu and Zn are enriched in Aβ deposits …

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

J Kang, HG Lemaire, A Unterbeck, JM Salbaum… - Nature, 1987 - nature.com
Alzheimer's disease1 is characterized by a widespread functional disturbance of the human
brain. Fibrillar amyloid proteins are deposited inside neurons as neurofibrillary tangles2 and …

Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

CA McLean, RA Cherny, FW Fraser… - Annals of …, 1999 - Wiley Online Library
Genetic evidence strongly supports the view that Aβ amyloid production is central to the
cause of Alzheimer's disease. The kinetics, compartmentation, and form of Aβ and its …

Imaging β-amyloid burden in aging and dementia

CC Rowe, S Ng, U Ackermann, SJ Gong, K Pike… - Neurology, 2007 - AAN Enterprises
Objective: To compare brain β-amyloid (Aβ) burden measured with [11C] Pittsburgh
Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias …